Peptide conjugated particles

• US 9,522,180 B2
• Filed: 04/03/2015
• Issued: 12/20/2016
• Est. Priority Date: 08/13/2013
• Status: Active Grant

• Current Assignee: Northwestern University
• Original Assignee: Northwestern University
• Inventors: Shea, Lonnie D., Miller, Stephen D., Yap, Jonathan Woon Teck, Getts, Daniel R., McCarthy, Derrick
• Primary Examiner(s): Navarro, Albert
• Assistant Examiner(s): NAVARRO, ALBERT MARK
• Application Number:
  US14/678,863
• Publication Number:
  US 20150283218A1
• Time in Patent Office: 627 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/577 tolerising response
• CPC Class Codes: A61K 2039/622 non-covalent binding
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0008 Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• CPC Class Codes: A61K 47/58 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: A61K 47/6937 the polymer being PLGA, PLA or polyglycolic acid
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61K 9/5153 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 5/06 : of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 : Antianaemics

Abstract

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

Claims

1. A composition comprising surface functionalized biodegradable poly(lactide-co-glycolide) (PLG) particles comprising encapsulated desmoglein 1 and/or desmoglein 3 polypeptides or one or more epitopes thereof, wherein the particle has a negative zeta potential.

2. The composition of claim 1 wherein the desmoglein 1 and/or desmoglein 3 is desmoglein 3 (DSG3).

3. The composition of claim 1, wherein the particles comprise PLG with a copolymer ratio of about 50:

50 of polylactic acid;

polyglycolic acid.

4. The composition of claim 1, wherein the surface functionalization is carboxylation.

5. The composition of claim 4, wherein the carboxylation is achieved by using poly(ethylene-maleic anhydride) (PEMA).

6. The composition of claim 1, wherein the particles have a zeta potential of about −

100 mV to about −

50 mV.

7. The composition of claim 1, wherein the particles have a zeta potential of about −

75 mV to about −

50 mV.

8. The composition of claim 1, wherein the particle has a diameter of between about 200 nm to about 2000 nm.

18. The composition of claim 1, wherein said particles encapsulate a desmoglein 3 polypeptide.

19. The composition of claim 1, wherein said particles encapsulate a desmoglein 1 polypeptide.

9. A composition comprising surface functionalized biodegradable PLG particles comprising encapsulated desmoglein 3 polypeptides or one or more epitopes thereof wherein said PLG particles have a copolymer ratio of about 50:

50 poly(lactide-co-glycolide), a diameter of about 200 nm to about 2000 nm and a zeta potential of about −

50 mv to about −

75 mv.

10. A lyophilized composition comprising surface functionalized biodegradable poly(lactide-co-glycolide) (PLG) particles comprising encapsulated desmoglein 1 and/or desmoglein 3 polypeptides or one or more epitopes thereof, herein the particle has a negative zeta potential.

11. The lyophilized composition of claim 10 wherein the desmoglein is desmoglein 3.

12. The lyophilized composition of claim 10, wherein the particles comprise PLG with a copolymer ratio of about 50:

50 of polylactic acid;

polyglycolic acid.

13. The lyophilized composition of claim 10, wherein the surface functionalization is carboxylation.

14. The lyophilized composition of claim 13 wherein the carboxylation is achieved by using poly(ethylene-maleic anhydride) (PEMA).

15. The lyophilize composition of claim 10, wherein the particles have a zeta potential of about −

100 mv to about −

50 mV.

16. The lyophilized composition of claim 10, wherein the particle has a diameter of between about 200 nm to about 2000 nm.

17. A lyophilized composition comprising surface functionalized biodegradable poly(lactide-co-glycolide) (PLG) particles comprising encapsulated desmoglein 3 polypeptide or one or more epitopes thereof wherein said PLG particles have a copolymer ratio of about 50:

50 poly(lactide-co-glycolide), a diameter of about 200 nm to about 2000 nm and a zeta potential of about −

50 mv to about −

100 mv.